Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.52 and traded as high as $1.66. Cortexyme shares last traded at $1.60, with a volume of 2,685,194 shares trading hands.
Cortexyme Stock Up 2.6%
The firm has a 50-day moving average of $1.70 and a 200 day moving average of $1.52. The stock has a market capitalization of $48.24 million, a P/E ratio of -0.54 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Stories
- Five stocks we like better than Cortexyme
- Comparing and Trading High PE Ratio Stocks
- CoreWeave’s Guidance Cut: A Buying Opportunity in Disguise?
- How to Plot Fibonacci Price Inflection Levels
- Strategy Shares Plunge as Bitcoin Retreats—More Pain Ahead?
- Trading Stocks: RSI and Why it’s Useful
- BigBear.ai Stock Is Range-Bound—Wall Street Isn’t Buying the Hype
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
